You are here

Ann N Y Acad Sci DOI:10.1111/j.1749-6632.2011.06216.x

Advancing drug discovery for schizophrenia.

Publication TypeJournal Article
Year of Publication2011
AuthorsMarder, SR, Roth, B, Sullivan, PF, Scolnick, EM, Nestler, EJ, Geyer, MA, Welnberger, DR, Karayiorgou, M, Guidotti, A, Gingrich, J, Akbarian, S, Buchanan, RW, Lieberman, JA, P Conn, J, Haggarty, SJ, Law, AJ, Campbell, B, Krystal, JH, Moghaddam, B, Sawa, A, Saw, A, Caron, MG, George, SR, Allen, JA, Solis, M
JournalAnn N Y Acad Sci
Date Published2011 Oct
KeywordsAnimals, Antipsychotic Agents, Disease Models, Animal, Drug Discovery, Epigenomics, Genome-Wide Association Study, Humans, Models, Biological, Molecular Targeted Therapy, New York, Research, Research Design, Schizophrenia

Sponsored by the New York Academy of Sciences and with support from the National Institute of Mental Health, the Life Technologies Foundation, and the Josiah Macy Jr. Foundation, "Advancing Drug Discovery for Schizophrenia" was held March 9-11 at the New York Academy of Sciences in New York City. The meeting, comprising individual talks and panel discussions, highlighted basic, clinical, and translational research approaches, all of which contribute to the overarching goal of enhancing the pharmaceutical armamentarium for treating schizophrenia. This report surveys work by the vanguard of schizophrenia research in such topics as genetic and epigenetic approaches; small molecule therapeutics; and the relationships between target genes, neuronal function, and symptoms of schizophrenia.


Alternate JournalAnn. N. Y. Acad. Sci.
PubMed ID22032400
PubMed Central IDPMC3787879
Grant ListR01 DA007223 / DA / NIDA NIH HHS / United States
R01 MH095088 / MH / NIMH NIH HHS / United States
R01 NS031373 / NS / NINDS NIH HHS / United States